AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
AbbVie announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a…
Read More...
Read More...
